Serum YKL-40and P185Combined Detection In Early Diagnosis Of Ovarian Cancer

Background and Purpose: Ovarian cancer (Ovarian canaer, OC) is acommon gynecological malignancies,90%of ovarian cancers are epithelialovarian cancer (Epithelial Ovarian canaer, EOC), the mortality rate atthe head of three common gynecologic malignancies ovarian cancer comparedto cervical cancer onset and occult endometrial cancer, the deeper parts,the clinical symptoms and signs are not typical, and the lack of effectivemethods for early diagnosis and prone to many parts of metastasis andinvasion, most patients already found late,5-year survival in advancedovarian cancer is only about30%. The early ovarian cancer5-year survivalrate of90%, so look for the early diagnosis of ovarian cancer serum tumormarkers for early diagnosis and timely treatment of ovarian cancer issignificant. P185is the HER-2/neu oncogene or e-errbB-2encodedglycoprotein. Amplification of oncogenes e-errbB-2and (or)overexpression can lead to uncontrolled cell growth and invasiveness oftumor cells produced, preventing apoptosis of tumor cells and promotetheir growth. Serum soluble P185can be used for detecting the detectionof malignant tumors. YKL-40that human cartilage protein39(Humancartilage glycoprotein-39; HCgp-39), is a mammalian chitinase-likeprotein substances involved in human tissue cell proliferation,differentiation, growth, anti-apoptosis, invasion and metastasis,angiogenesis, various inflammatory cell activity and life-like tumorcells constitute the extracellular matrix. In this study, enzyme-linkedimmunosorbent assay and electrochemiluminescence immunoassay for normalovarian tissue, benign ovarian tumors, ovarian cancer serum YKL-40, P185 levels were detected, and their relationship with clinical stages ofovarian cancer were analyzed separately To investigate the expression ofboth in ovarian cancer and ovarian cancer, development and metastasis.Combined detection of further explored in the early stages of clinicaldiagnosis and clinical significance of ovarian cancer.Methods: Sino-Japanese Friendship Hospital of Jilin University,Jilin Province Tumor Hospital clinical and pathological diagnosis ofovarian cancer January2012to October2013blood samples of62patientswith ovarian cancer,60cases of benign ovarian tumors and60cases ofexamination of blood samples of healthy women as a control group weremeasured by enzyme-linked immunosorbent assay andelectrochemiluminescence immunoassay serum YKL-40, P185levels. Allstudy subjects were collected in the morning fasting blood3ml bloodsamples were collected using non-anticoagulant tube. After taking blood,blood coagulation at room temperature for at least30to1minutes. Whenthe natural precipitation of serum at4℃,2000rev/min, centrifuged10minutes, serum was extracted, the insoluble matter discarded. EP serumto a clean tube, well marked,-20℃storage until use. All serum samplesto avoid hemolysis and repeated freezing and thawing.Data analysisapplications SPSS19.0statistical package for statistical analysis of thedata.Results:1.Serum YKL-40, P185in patients with ovarian cancer, the positiveexpression rates were75.81%,80.65%. After statistical analysis,patients with ovarian cancer in the YKL-40and P185levels higher thannormal ovarian tissues and benign ovarian tumor group, the difference wassignificant (P <0.01), whereas no correlation between ovarian tumors and normal control group statistically significant (P>0.05).2. Serum YKL-40, P185than the combined detection of any oneindividually tested positive rate rose up to91.94%, in which the positiverate of Phase I and Phase II testing in patients with ovarian cancer ashigh as91.43%for stage III and stage IV the positive rate of patientswith ovarian cancer detection up to92.59%.3.The positive rate of combined detection of ovarian cancer serumYKL-40and P185levels, independent of ovarian cancer clinical stage,pathological type, degree of differentiation.Conclusion:1.Elevated serum YKL-40and P185may indicate ovarian cancer anddevelopment.2.Serum YKL-40, P185three joint detection can effectively improvethe sensitivity for early diagnosis of ovarian cancer.